

Title (en)  
Internalising immunoglobulin

Title (de)  
Internalisierendes Immunglobulin

Title (fr)  
Immunoglobuline s'internalisant

Publication  
**EP 2546268 A1 20130116 (EN)**

Application  
**EP 11173784 A 20110713**

Priority  
EP 11173784 A 20110713

Abstract (en)  
The disclosure relates to internalising modular antibody based on one or more immunoglobulin domains, which comprises at least one binding structure located within the N-terminal portion of a domain, and comprises at least one binding structure acting as a binding site located within the non-CDR region of a domain, wherein a) a first binding structure has a specificity to bind an extra-cellular portion of a receptor on a tumor cell, and b) a second binding structure has a specificity to bind a soluble tumor associated antigen (sTAG), and an Fc fragment of an immunoglobulin, which binds to an EGFR epitope.

IPC 8 full level  
**C07K 16/28** (2006.01); **C07K 16/22** (2006.01); **C07K 16/46** (2006.01); **C07K 19/00** (2006.01)

CPC (source: EP)  
**C07K 16/22** (2013.01); **C07K 16/2863** (2013.01); **C07K 16/2875** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/524** (2013.01); **C07K 2317/526** (2013.01); **C07K 2317/53** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/77** (2013.01); **C07K 2317/92** (2013.01); **C07K 2318/20** (2013.01)

Citation (applicant)  
• WO 2006072620 A1 20060713 - RUEKER FLORIAN [AT], et al  
• WO 2008003103 A2 20080110 - F STAR BIOTECH FORSCH & ENTW [AT], et al  
• WO 9720858 A1 19970612 - AMGEN INC [US]  
• WO 2006087637 A2 20060824 - HELLENIC PASTEUR INST [GR], et al  
• WO 2006036834 A2 20060406 - AMGEN INC [US]  
• WO 2009132876 A1 20091105 - F STAR BIOTECH FORSCH & ENTW [AT], et al  
• WO 2005123104 A2 20051229 - REGENERON PHARMA [US], et al  
• WO 2011017294 A1 20110210 - SCHERING CORP [US], et al  
• US 2010009390 A1 20100114 - MARKS JAMES D [US], et al  
• ROVERS ET AL., CANCER IMMUNOL. IMMUNOTHER, vol. 56, 2007, pages 303 - 317  
• CANON ET AL., BONE, vol. 46, no. 6, 2010, pages 1613 - 9  
• DONG ET AL.: "DOI: 10.4161 /mabs.3.3.15188", MABS, vol. 3, 2011, pages 3  
• GOENAGA ET AL., MOL IMMUNOL., vol. 44, no. 15, 2007, pages 3777 - 3788  
• LEFRANC ET AL.: "IMGT, the international ImMunoGeneTics", NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212  
• YANEZ ET AL., NUCLEIC ACIDS RES., vol. 32, 2004, pages E158  
• VIRNEKAS ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 5600 - 5607  
• KUNKEL TA: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI U S A., vol. 82, no. 2, January 1985 (1985-01-01), pages 488 - 92  
• WEINER MP, COSTA GL, SCHOETTLIN W, CLINE J, MATHUR E, BAUER JC: "Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction.", GENE, vol. 151, no. 1-2, 30 December 1994 (1994-12-30), pages 119 - 23  
• "Antibody Engineering", SPRINGER-VERLAG  
• HAYHURST, GEORGIU, CURR OPIN CHEM BIOL, vol. 5, 2001, pages 683 - 689  
• MAYNARD, GEORGIU, ANNU REV BIOMED ENG, vol. 2, 2000, pages 339 - 76  
• WITTRUP, CURR OPIN BIOTECHNOL, vol. 12, 2001, pages 395 - 399  
• ADAIR JR, ATHWAL DS, BODMER MW, BRIGHT SM, COLLINS AM, PULITO VL, RAO PE, REEDMAN R, ROTHERMEL AL, XU D ET AL., HUM ANTIBODIES HYBRIDOMAS., vol. 5, no. 1-2, 1994, pages 41 - 7

Citation (search report)  
• [XY] WO 2008124858 A2 20081023 - F STAR BIOTECH FORSCH & ENTW [AT], et al  
• [ID] WO 2009132876 A1 20091105 - F STAR BIOTECH FORSCH & ENTW [AT], et al  
• [Y] WO 2007080392 A2 20070719 - DOMANTIS LTD [GB], et al  
• [Y] WO 2009068649 A2 20090604 - GLAXO GROUP LTD [GB], et al  
• [A] WO 2011003811 A1 20110113 - STAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTWICKLUNGSGES M B H F [AT], et al  
• [Y] ZHANG HONGZHENG ET AL: "A novel dual targeting antibody against EGFR and VEGF (DMS3008) in lung and head and neck cancer cell lines", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 49, 1 April 2008 (2008-04-01), pages 566, XP001537362, ISSN: 0197-016X  
• [Y] YUN SUJIN ET AL: "A dual antibody against EGFR and VEGF as a therapeutic agent for cancer treatment", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 49, 1 April 2008 (2008-04-01), pages 566 - 567, XP001537363, ISSN: 0197-016X  
• [A] BHASKAR V ET AL: "E-selectin up-regulation allows for targeted drug delivery in prostate cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6387 - 6394, XP002280964, ISSN: 0008-5472  
• [A] TRACEY ET AL: "Tumor necrosis factor antagonist mechanisms of action: A comprehensive review", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 117, no. 2, 26 October 2007 (2007-10-26), pages 244 - 279, XP022432143, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2007.10.001

Cited by  
CN113968896A; EP3710467A4; CN109476746A; JP2020503860A; EP4130037A1; WO2022123001A1; WO2018015448A1; WO2018127610A1; WO2024023340A1; WO2022248380A1; US11629193B2; US12037416B2; US11214620B2; WO2022175413A1; US11548948B2; US10633458B2;

US10640576B2; US10654944B2; US10836833B2; US11214618B2; US12103976B2; US9656983B2; WO2021032963A1; WO2022034562A1; EP4218932A2; EP4265642A2; EP4265643A2; EP4269444A2; EP4269446A2; EP4269445A2; US11795232B2; US11912778B2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**EP 2546268 A1 20130116**

DOCDB simple family (application)

**EP 11173784 A 20110713**